Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline and Isis agree partnership on new drug developments

GlaxoSmithKline and Isis agree partnership on new drug developments

6th April 2010

GlaxoSmithKline is to utilise an antisense drug discovery platform from Isis Pharmaceuticals in a research partnership into new therapeutic options.

The collaboration will include up to six separate programmes and is aimed at inhibiting the proteins involved in disease processes by targeting RNA.

Isis has received an upfront payment of $35 million (23.1 million) for the use of its platform and will receive milestone payments up to $1.5 billion should all six programmes be successfully developed into products.

The companies have identified the platform as a promising means of treating rare and infectious diseases, with Isis having already produced a promising hypercholesterolemia therapy using this method.

Dr Patrick Vallance, senior vice-president and head of drug discovery at GlaxoSmithKline, said: “As a platform, the Isis antisense approach offers us an exciting opportunity to target certain severe diseases in a way that has not previously been possible.”

Last week, the company received approval from European regulators for the sale of Duodart, a new treatment for benign prostatic hyperplasia.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.